Rizatriptan Benzoate Tablet
Product Images NDC 71335-1149

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 71335-1149). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image (Lbl713351149)

Label Image (Lbl713351149)
Label for Rizatriptan Benzoate 5 mg Tablet by Bryant Ranch Prepack. The label indicates comparison to Maxalt 5 mg Tablet Blister pack by Rising Health LLC. It includes storage instructions, a barcode, lot number 1523487, and NDC 71335-1149. The tablet is pink and round, packaged in a quantity of 30.*
FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)
A Kaplan-Meier plot showing the estimated probability of achieving an initial headache response by 2 hours after dosing for rizatriptan benzoate 5 mg, rizatriptan benzoate 10 mg, and placebo. The graph tracks response probabilities over time from 0 to 2 hours based on pooled data from four placebo-controlled outpatient studies.*
FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)
A Kaplan-Meier plot showing the estimated probability of patients taking a second dose of Rizatriptan Benzoate tablets or other medication for migraines within 24 hours after the initial dose. The graph compares placebo, 5 mg Rizatriptan Benzoate, and 10 mg Rizatriptan Benzoate groups, with time post-dose in hours on the x-axis and estimated probability on the y-axis.*
FDA Label Image

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig3)

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig3)
Line graph titled 'Observed Percentage of Patients Reporting No Headache Pain by 2 Hours Post-Dose in Study 7,' comparing Rizatriptan Benzoate Orally Disintegrating Tablets and placebo. The x-axis shows hours post Stage 2 dose (0.5 to 2.0) and the y-axis shows percent (0 to 100%). Rizatriptan demonstrates higher percentages of patients reporting no headache pain over time compared to placebo, with error bars indicating 95% confidence intervals.*
FDA Label Image

Chemical Structure (Rizatriptan Str)

Chemical Structure (Rizatriptan Str)
Chemical structure of Rizatriptan Benzoate showing its molecular components and arrangement, including a benzoic acid moiety indicated by the COOH group attached to a benzene ring.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.